ARASTEP: A Study to Compare Darolutamide Given With ADT vs ADT Alone in Men With Nonmetastatic Prostate Cancer

The ARASTEP Study: Evaluating the Treatment of Biochemically Recurrent Disease in nmHSPC Patients- Alicia Morgans

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer

Condition: Biochemically Recurrent Prostate Cancer
Study ID: NCT05794906

Conference Coverage

Conference Highlights Written by Physician-Scientist